AEX-1: A Vero cell variant with enhanced permissiveness for influenza virus replication
Veterinary vector track record — Tabynov K. et al. “Influenza viral vectors expressing the Brucella OMP16 or L7/L12 proteins as vaccines against B. abortus infection.” Virology Journal 11 (2014), 69. https://doi.org/10.1186/1743-422X-11-69
Phase I clinical evidence — Stukova M. et al. “Phase 1 evaluation of UniFluVec: safety and reactogenicity of an intranasal universal influenza vector vaccine at two dose levels.” MIR Journal (2025), 12(1):68–79. https://doi.org/10.18527/20251216879
Heterosubtypic influenza protection — Ferko B. et al. “UniFluVec influenza vector induces heterosubtypic protection in ferrets after intranasal administration despite high attenuation.” MIR Journal (2024), 11(1):70–79. https://doi.org/10.18527/2024117079
Related vector / SARS-CoV-2 — Egorov A. et al. “Single intranasal immunization with a high dose of influenza vector protects against infection with heterologous influenza virus and SARS-CoV-2 in ferrets and hamsters.” MIR Journal (2024), 11(1):10–24. https://doi.org/10.18527/2024111024
Related vector / RSV — Pulkina A. et al. “IgGκ Signal Peptide Enhances the Efficacy of an Influenza Vector Vaccine against Respiratory Syncytial Virus Infection in Mice.” International Journal of Molecular Sciences (2023), 24:11445. https://doi.org/10.3390/ijms241411445
Influenza vector immunology — Ferko B. et al. “Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes.” Journal of Virology (2004), 78:13037–13045. https://doi.org/10.1128/JVI.78.23.13037-13045.2004